Company: IMRX
Filing Date: 2025-09-24
Form Type: 8-K
Source: 0001104659-25-092957
Chunk: 2

Company: Immuneering Corp
Filing Date: 2025-09-24
Form: 8-K
Item: Item 1.01
Chunk 2
---
 all voting securities of the Company as to which it
is entitled to vote in accordance with the recommendation of a majority of the Company’s board of directors.

Under the terms of the Purchase Agreement, notwithstanding anything
set forth in the Company’s certificate of incorporation, the Investor will not be entitled to exercise any conversion of Class B
Shares into shares of Class A Common Stock if, upon giving effect to such conversion, the aggregate number of shares of Class A Common
Stock beneficially owned by the Investor (together with its affiliates, any other persons acting as a group together with the Investor
or any other attribution party with respect the Investor) would exceed 4.99% of the number of shares of Class A Common Stock outstanding
immediately after giving effect to such conversion, as such percentage ownership is determined in accordance with the terms of the Purchase
Agreement, which percentage may be increased at the Investor’s election upon 61 days’ notice to the Company, provided that
such percentage may in no event exceed 9.9% (the “ Beneficial Ownership Limitation”).

The Private Placement is exempt from registration pursuant to Section
4(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act”), and corresponding provisions of state securities
or “blue sky” laws, as a transaction by an issuer not involving a public offering. The Investor represented that it was acquiring
the Shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof.
Accordingly, the Shares have not been registered under the Securities Act and such securities may not be offered or sold in the United
States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Appropriate
legends have been affixed to the securities issued in this transaction.

The representations, warranties and covenants contained in the Purchase
Agreement were made solely for the benefit of the parties thereto and may be subject to limitations agreed upon by the contracting parties.
Accordingly, the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms
of the Purchase Agreement, and not to provide investors with any other factual information regarding the Company or its business, and
should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.

The foregoing description of the Purchase Agreement does not purport
to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement,